Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P427: Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximabECCO '17 Barcelona
Year: 2017
Authors:

Nishida Y.*1, Hosomi S.1, Watanabe K.2, Yukawa T.1, Otani K.1, Nagami Y.1, Tanaka F.1, Taira K.1, Kamata N.1, Shiba M.1, Yamagami H.1, Tanigawa T.1, Watanabe T.1, Tominaga K.1, Fujiwara Y.1

1Osaka City University, Gastroenterology, Osaka, Japan 2Osaka General Hospital, Osaka, Japan

P428: Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian populationECCO '17 Barcelona
Year: 2017
Authors:

Mao R.1, Guo J.1, Ben Horin S.1,2, Chen M.*3

1The first affiliated hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China 2Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel 3The first affiliated hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P429: Mucosal healing after 3 months of conventional IBD treatment: real life dataECCO '17 Barcelona
Year: 2017
Authors:

Carlsen A.*1, Tvedt-Gundersen E.1, Isaksen K.1, Leitao K.Ø.1, Karlsen L.N.1, Omdal R.1,2, Aabakken L.3, Grimstad T.1

1Stavanger University Hospital, Department of Internal Medicine, Stavanger, Norway 2University of Bergen, Department of Clinical Science, Bergen, Norway 3Oslo University Hospital, Deaprtment of Gastroenterology, Oslo, Norway

P430: EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experienceECCO '17 Barcelona
Year: 2017
Authors:

Nugent S.*1, Nugent M.2, Mullane D.1, Kelly C.1

1Whitfield Clinic, Gastroenterology, Waterford, Ireland 2Trinity College Dublin, Medical School, Dublin, Ireland

P431: Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab doseECCO '17 Barcelona
Year: 2017
Authors:

Fuh F., Tew W., Keir M., Looney C., Maciuca R., McBride J., Ramirez-Montagut T.

Genentech, South San Francisco, United States

P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Sebastian S.*1,2, Tzivinikos C.3, Drskova T.4, Hradsky O.4, Nair M.V.1,5, Sahnan K.6, Muhammed R.7, Devadason D.8, Parmar R.S.3, Crook K.6, Akbar A.6, Thomson M.5, Hart A.L.6

1Hull & East Yorkshire NHS Trust, Hull, United Kingdom 2Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom 3Alder Hey Children's Hospital, Liverpool, United Kingdom 4Motol University Hospital, Prague, Czech Republic 5Sheffied Children's Hospitals NHS Foundation Trust, Sheffiled, United Kingdom 6St Marks Hospital, London, United Kingdom 7Birmingham Children's Hospital, Birmingham, United Kingdom 8Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII groupECCO '17 Barcelona
Year: 2017
Authors:

García Albert A.M.1, García-Paredes R.*2, Torrella Cortés E.3, Martinez-Jimenez T.4, Angel Rey J.M.4, García-Tercero I.2, Castillo Espinosa J.M.5, Torregrosa Lloret M.3, Chacόn Martínez S.3, Andreu Plaza J.6, Rodríguez Lozano A.2

1Reina Sofía-Murcia Hospital, Gastroenterology, Murcia, Spain 2Santa Lucía Hospital, Gastroenterology, Cartagena, Spain 3Morales Meseguer Hospital, Gastroenterology, Murcia, Spain 4Rafael Mendez Hospital, Gastroenterology, Lorca, Spain 5Los Arcos Hospital, Digestive Disease, Cartagena, Spain 6Virgen del Castillo Hospital, Gastroenterology, Yecla, Spain

P434: Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year periodECCO '17 Barcelona
Year: 2017
Authors:

Chew T.S.*1, Carmichael M.S.1, Hoare T.W.2, Waugh J.3, Gunn M.C.1

1Royal Victoria Infirmary, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom 2Royal Victoria Infirmary, Department of Radiology, Newcastle upon Tyne, United Kingdom 3Royal Victoria Infirmary, Department of Obstetric and Gynaecology, Newcastle upon Tyne, United Kingdom

P435: The mean corpuscular volume flow – prognostic value for inflammatory bowel disease under thiopurine treatmentECCO '17 Barcelona
Year: 2017
Authors:

Roseira J.*1, Tavares de Sousa H.1, Marreiros A.2, Queiros P.1, Vaz A.M.1, Gago T.1, Contente L.1, Guerreiro H.1

1Algarve Hospital Centre, Gastroenterology, Algarve, Portugal 2Universidade do Algarve, Biomedical Science, Algarve, Portugal

P436: Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practiceECCO '17 Barcelona
Year: 2017
Authors:

Jimenez M.*1, Sierra-Ausin M.1, Cano N.1, Suarez P.1, Fernandez-Gundin M.1, Saez-Villafañe M.2, Monteserin L.1, Molina G.1, Reyes N.1, Viso D.1, Jorquera F.1

1Hospital Universitario de Leόn, Gastroenterology, Leόn, Spain 2Hospital Universitario de Leόn, Pharmacoloy, Leόn, Spain

P437: Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapseECCO '17 Barcelona
Year: 2017
Authors:

Lόpez García A.*1, Rovira M.2, Jauregui Amezaga A.1, Marin P.3, Barastegui R.1, Salas A.1, Feu F.1, Elizalde J.1, Fernández-Avilés F.2, Martínez C.4, Gutierrez G.2, Rosiñol L.2, Carreras E.2, Urbano A.2, Lozano M.3, Cid J.3, Suárez-Lledό M.2, Masamunt M.C.1, Comas D.1, Giner A.1, Gallego M.1, Alfaro I.1, Ordás I.1, Panés J.1, Ricart E.1

1Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain 2Hospital Clinic Barcelona, Hematology, Barcelona, Spain 3Hospital Clinic Barcelona, Biomedic Diagnostic Center, Barcelona, Spain 4Hospital Clinic Barcelona, Gynecology, Barcelona, Spain

P438: Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Van de Vondel S.*1, Baert F.2, Reenaers C.3, Bossuyt P.4, Hindryckx P.5, Vanden Branden S.6, Amininejad L.7, Dewint P.8, Rahier J.F.9, Ferrante M.1 Belgian IBD Research and Development

1University Hospitals Leuven, Dept of Gastroenterology, Leuven, Belgium 2AZ Delta, Dept of Gastroenterology, Roeselare, Belgium 3University Hospital CHU of Liège, Dept of Gastroenterology, Liège, Belgium 4Imelda Hospital, Dept of Gastroenterology, Bonheiden, Belgium 5Ghent University Hospital, Dept of Gastroenterology, Gent, Belgium 6Onze-Lieve-Vrouw Hospital, Dept of Gastroenterology, Aalst, Belgium 7Erasme Hospital, Université Libre de Bruxelles, Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium 8AZ Maria Middelares, Dept of Gastroenterology, Gent, Belgium 9CHU Dinant Godinne, UCL Namur, Dept of Gastroenterology, Yvoir, Belgium

P439: Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Thi A.A.*1, Bouri S.1, Wolfson P.1, Owen L.1, Abbara A.2, John L.2, Davidson R.2, Hart A.1

1St Mark's Hospital, London, United Kingdom 2Northwick Park Hospital, London, United Kingdom

P440: Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter studyECCO '17 Barcelona
Year: 2017
Authors:

Pugliese D.*1, Armuzzi A.1, Panici Tonucci T.1, Tolusso B.2, Felice C.1, Papa A.1, Cantoro L.3, Balestrieri P.4, Civitelli F.5, Bertani L.6, Kohn A.3, Cicala M.4, Viola F.5, Costa F.6, Rapaccini G.L.1, Guidi L.1

1Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, UOC Gastroenterologia Presidio Columbus, Rome, Italy 2Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, UOC Reumatologia Presidio Columbus, Rome, Italy 3AO San Camillo Forlanini, IBD Unit, Rome, Italy 4Campus BioMedico, University of Rome, Department of Gastroenterology, Rome, Italy 5Università La Sapienza, UOC Pediatric Gastroenterology, Rome, Italy 6AOU Pisana, UOC Gastroenterologia Universitaria, Pisa, Italy

P441: Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label studyECCO '17 Barcelona
Year: 2017
Authors:

Mao R.*1, He Y.1, Ben-Horin S.2, Chen M.-h.1

1First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 2Sheba Medical Center, Tel-aviv, Israel

P442: Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experienceECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.1, Bhayat F.*2, Khalid J.M.3, Palo W.4, Blake A.5, Shetzline M.6, Travis S.7

1Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 2Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom 3Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 4Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States 5Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 6Takeda Pharmaceuticals International Co., Clinical Science, GI, Cambridge, United States 7University of Oxford, Translational Gastroenterology Unit, Nuffield Department of Medicine, Oxford, United Kingdom

P443: Systematic review of internet decision making resources for patients considering surgery for ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Baker D.*1, Marshall J.1, Lee M.2, Jones G.3, Brown S.2, Lobo A.4

1University of Sheffield Medical School, Sheffield, United Kingdom 2Sheffield Teaching Hospitals, General Surgery, Sheffield, United Kingdom 3Leeds Beckett University, Leeds, United Kingdom 4Sheffield Teaching Hospitals, Academic Unit of Gastroenterology, Sheffield, United Kingdom

P444: Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patientsECCO '17 Barcelona
Year: 2017
Authors:

Johnston E.*1, Warner B.1, Fong S.1, Arenas-Hernandez M.2, Marinaki A.2, Anderson S.1, Sanderson J.1, Irving P.1

1IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom 2Viapath Pathology Services, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom

P445: Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosisECCO '17 Barcelona
Year: 2017
Authors:

Schils N.*1, De Buck van Overstraeten A.2, Vermeire S.1, Van Assche G.1, Wolthuis A.2, D'Hoore A.2, Ferrante M.1

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium

P446: Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54ECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Rutgeerts P.2, Zhang H.3, Adedokun O.J.3, Xu S.3, Shraim R.3, Marano C.*3

1University of California, San Diego, United States 2University Hospital, Gasthuisberg, Leuven, Belgium 3Janssen Research & Development, LLC, Spring House, United States